Information Provided By:
Fly News Breaks for October 14, 2019
Oct 14, 2019 | 09:16 EDT
SunTrust analyst Joon Lee raised his price target on Global Blood Therapeutics to $100 and kept his Buy rating after the company's Analyst and Investor Day event. The analyst notes that the discussion regarding the expected approval of hemoglobin modifier voxelotor for sickle cell disease has further de-risked his approvability projections, and he expects the drug to change the treatment paradigm of the condition where the standard of care has been "stagnant for the past few decades."
News For GBT From the Last 2 Days
There are no results for your query GBT